

Glucocorticoid activation by 11 β -hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: A cross-sectional study

Sagmeister, Michael; Taylor, Angela; Fenton, Anthony; Wall, Nadezhda; Chanouzas, Dimitrios; Nightingale, Peter; Ferro, Charles J; Arlt, Wiebke; Cockwell, Paul; Hardy, Rowan; Harper, Lorraine

DOI:
[10.1111/cen.13889](https://doi.org/10.1111/cen.13889)

License:
Creative Commons: Attribution (CC BY)

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):
Sagmeister, M, Taylor, A, Fenton, A, Wall, N, Chanouzas, D, Nightingale, P, Ferro, CJ, Arlt, W, Cockwell, P, Hardy, R & Harper, L 2019, 'Glucocorticoid activation by 11 β -hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: A cross-sectional study', *Clinical Endocrinology*, vol. 90, no. 1, pp. 241-249. <https://doi.org/10.1111/cen.13889>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:
Checked for eligibility 07/12/2018
<https://doi.org/10.1111/cen.13889>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.


Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

ORIGINAL ARTICLE

Glucocorticoid activation by 11 β -hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: A cross-sectional study

Michael S. Sagmeister^{1,2} | Angela E. Taylor³ | Anthony Fenton^{1,2} | Nadezhda A. Wall⁴ | Dimitrios Chanouzas^{1,2} | Peter G. Nightingale⁵ | Charles J. Ferro² | Wiebke Art³ | Paul Cockwell² | Rowan S. Hardy^{3,6*}  | Lorraine Harper^{2,4*}

¹Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK

²Department of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

³Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK

⁴Institute of Clinical Sciences, University of Birmingham, Birmingham, UK

⁵Institute of Translational Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

⁶Institute of Inflammation and Ageing, ARUK Rheumatoid Arthritis Centre of Excellence, and MRC ARUK Centre for Musculoskeletal Ageing, University of Birmingham, Birmingham, UK

Correspondence

Rowan S. Hardy, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.
Email: r.hardy@bham.ac.uk

Funding information

Arthritis Research UK, Grant/Award Number: 20843; JABBS Foundation (Birmingham, United Kingdom); The Queen Elizabeth Hospital Birmingham Charity; National Institute for Health Research UK; Wellcome Trust, Grant/Award Number: 105479/Z/14/Z

Summary

Objective: Patients with chronic kidney disease (CKD) have dysregulated cortisol metabolism secondary to changes in 11 β -hydroxysteroid dehydrogenase (11 β -HSD) enzymes. The determinants of this and its clinical implications are poorly defined.

Methods: We performed a cross-sectional study to characterize shifts in cortisol metabolism in relation to renal function, inflammation and glycaemic control. Systemic activation of cortisol by 11 β -HSD was measured as the metabolite ratio (tetrahydrocortisol [THF]+5 α -tetrahydrocortisol [5 α THF])/tetrahydrocortisone (THE) in urine.

Results: The cohort included 342 participants with a median age of 63 years, median estimated glomerular filtration rate (eGFR) of 28 mL/min/1.73 m² and median urine albumin-creatinine ratio of 35.5 mg/mmol. (THF+5 α THF)/THE correlated negatively with eGFR (Spearman's $\rho = -0.116$, $P = 0.032$) and positively with C-reactive protein ($\rho = 0.208$, $P < 0.001$). In multivariable analysis, C-reactive protein remained a significant independent predictor of (THF+5 α THF)/THE, but eGFR did not. Elevated (THF+5 α THF)/THE was associated with HbA1c ($\rho = 0.144$, $P = 0.008$) and diabetes mellitus (odds ratio for high vs low tertile of (THF+5 α THF)/THE 2.57, 95% confidence interval 1.47-4.47). Associations with diabetes mellitus and with HbA1c among the diabetic subgroup were independent of eGFR, C-reactive protein, age, sex and ethnicity.

Conclusions: In summary, glucocorticoid activation by 11 β -HSD in our cohort comprising a spectrum of renal function was associated with inflammation and impaired glucose control.

*Rowan S. Hardy and Lorraine Harper are joint senior authors.

1 | INTRODUCTION

Glucocorticoids (GCs) are steroid hormones that play a critical role in regulating energy metabolism, inflammation, cardiovascular function and behavioural processes. In excess, GCs drive metabolic disease, insulin resistance and cardiovascular disease.¹ Critical to the actions of GCs are their pre-receptor metabolism by the 11 β -hydroxysteroid dehydrogenase (11 β -HSD) type 1 and type 2 enzymes.² 11 β -HSD1 is a bidirectional enzyme that primarily converts inactive GC (cortisone) to its active counterpart (cortisol) and is widely expressed throughout the body.³ In contrast, 11 β -HSD2 solely inactivates GCs and is primarily expressed in mineralocorticoid sensitive tissues such as the kidney. Together, these determine local tissue exposure.

Several studies have described a correlation between loss of renal function and GC activation by 11 β -HSD enzymes, measured as a rise in the ratio of cortisol/cortisone or a rise in the ratio of their respective metabolites (tetrahydrocortisol [THF]+5 α -tetrahydrocortisol [5 α THF])/tetrahydrocortisone (THE).^{4,5} Due to limitations of measuring steroid metabolism in this way, the relative contribution of each 11 β -HSD enzyme to the reported shift in cortisol metabolism is not known. Loss of renal expression of 11 β -HSD2 and diminished cortisol inactivation likely plays a role.⁶ However, *in vitro* and animal models of uraemia propose concurrent 11 β -HSD1 upregulation and associated cortisol generation.^{7,8}

Chronic kidney disease (CKD) entails a pro-inflammatory state.⁹ Pro-inflammatory cytokines are potent inducers of 11 β -HSD1 activity, promoting local GC activation both *in vitro* and *in vivo*.^{10,11} Upregulation of 11 β -HSD1 expression occurs in several human inflammatory conditions with a strong correlation between systemic measures of inflammation and increases in cortisol activation.^{12,14} Existing studies in CKD have not evaluated inflammation as a driver of 11 β -HSD1 activity or GC activation.

The inflammatory activation in CKD contributes to insulin resistance.^{15,16} Insulin resistance manifests from the early stages of renal impairment, and diabetes mellitus co-exists in one third of people with CKD.^{16,18,19} Disturbances in glucose metabolism in the context of CKD are independently associated with cardiovascular disease, accelerated loss of renal function and death.^{16,18,19} Elevated 11 β -HSD1 activity has been implicated in metabolic disease and insulin resistance.^{23,24} Suppression of 11 β -HSD1 activity protects against insulin resistance in murine models, including models of uraemia, and has improved HbA1c in Phase II clinical trials for type 2 diabetes.^{7,26,27} Whether elevated 11 β -HSD1 activity is involved in insulin resistance in the setting of human CKD has not yet been explored.

Given the central role of inflammation in regulating cortisol activation via 11 β -HSD1, we investigated its association with shifts in the cortisol-cortisone equilibrium in human CKD. Furthermore, we examined whether augmented GC activation in CKD relates to impaired glucose handling. To test this, we performed a cross-sectional study with 342 participants representing a broad spectrum of renal function. Using urine (THF+5 α THF)/THE as a validated indicator of systemic 11 β -HSD-mediated GC activation, we examined its correlation with renal function, inflammation and glycaemic control in CKD.^{5,30,31}

2 | MATERIALS AND METHODS

2.1 | Participants

This study included 331 participants with CKD and 11 healthy individuals without kidney disease. The Renal Impairment in Secondary Care (RIISC) observational study cohort provided the sampling frame for cases with CKD. Patient enrolment for RIISC took place at two teaching hospitals in Birmingham, United Kingdom, between 2010 and 2015. The eligibility criteria have been described in detail elsewhere.³³ In brief, patients in RIISC had CKD stage 3 with declining estimated glomerular filtration rate (eGFR) of ≥ 5 mL/min/1.73 m²/y or ≥ 10 mL/min/1.73 m²/5 y or proteinuria with urinary albumin-creatinine ratio (ACR) ≥ 70 mg/mmol, or CKD stage 4/5. Patients receiving renal replacement therapy or immunosuppressive treatment were excluded from the RIISC cohort. From a total of 932 cases in the RIISC cohort, 299 cases with incomplete biochemical data sets and 25 cases receiving systemic GC treatment were excluded prior to sampling. In total, 333 cases of 608 eligible cases were sampled for this study to obtain the desired sample size (see Statistical Analysis for power calculation). A stratified random sampling procedure was employed to balance the proportions of cases with eGFR ≤ 15 , 15-30, 30-45 and ≥ 45 mL/min/m² and to avoid oversampling cases from a narrow band of low eGFR which were preferentially enrolled in the RIISC cohort. Two cases had to be excluded in the experimental process due to technical failures.

Healthy individuals were recruited from the control arm of an ongoing study at the University of Birmingham characterizing immune dysfunction in older patients with CKD. These individuals did not have any known renal or inflammatory disease and were not using systemic GC treatment at the time of study enrolment. The rationale for inclusion of a small group of healthy individuals in analyses was to gain better insight into how changes in renal function affect glucocorticoid activation by 11 β -HSD, as cases with normal renal function and no active inflammation are underrepresented in the RIISC cohort.

Use of data and samples for this research falls under ethical approvals granted by the South Birmingham Local Research Ethics committee (participants with CKD; reference 10/H1207/6) and the Edgbaston Research Ethics Committee (participants without CKD; reference 15/WM/0057). All participants provided written informed consent, and the study was conducted in accordance with the Declaration of Helsinki.

2.2 | Baseline assessment

Study participants' demographic information, past medical history and concomitant medications were taken from medical records. Diabetes mellitus was defined by history of diet-controlled diabetes, treatment with anti-diabetic medications or HbA1c greater than 48 mmol/mol.

Laboratory measurements included routine blood haematological profiles (Haematology Analyser, Beckman Coulter, Brea, CA, USA) and blood biochemical profiles and urinary ACR (Roche Hitachi 702 Analyser, Basel, Switzerland). eGFR was derived from the serum creatinine-based CKD-EPI equation. CRP was measured using the Full Range C-Reactive Protein SpaPlus assay (The Binding Site, Birmingham, UK) for participants with CKD and the CRP High Sensitive ELISA (IBL, Hamburg, Germany) for volunteers without renal disease.

2.3 | Urinary steroid measurements

The balance of systemic (ie, total body) cortisol-cortisone interconversion by 11 β -HSD enzymes was taken as the ratio calculated from the urinary excretion of (THF+5 α THF)/THE. This methodology is well established as reflective of 11 β -HSD1 activity and has previously been validated in the literature,^{30,31} including the use of early morning spot urine samples.^{5,34}

Spot urine samples were collected at morning clinic visits and stored at -80°C until analysis. Steroids were extracted from 400 μL of urine based on a previously reported protocol.³⁵ The urine was spiked with 0.4 μg of internal standard (THE-d5, THF-d5; purchased from Isosciences, Ambler, PA, USA), and the steroids hydrolysed to remove their conjugate groups (sulphate and/or glucuronide). This was achieved by heating the urine for 3 hours at 60°C in a hydrolysis buffer (400 μL of 0.2 mol/L acetate buffer pH 4.8-5: with 10 mg sulphatase [adjusted based on batch activity] and 10 mg ascorbate/3 mL of solvent). The now "free" deconjugated steroids were subsequently extracted by solid phase extraction using 96-well C₁₈ cartridges in a positive pressure manifold, eluting with 1 mL of methanol. The samples were dried at 50°C under nitrogen and reconstituted in 125 μL of 50/50 methanol/water for analysis with liquid chromatography-tandem mass spectrometry (uPLC-MS/MS).

A Waters Xevo mass spectrometer coupled to an Acquity uPLC with an electrospray ionization source in positive ionization mode was utilized in these experiments. THE, THF and 5 α THF were separated on a BEH C18 1.7 μm 5 cm column at 60°C with the mobile phases methanol and water both with 0.1% formic acid. Gradient profile was starting at 30% methanol, hold for one minute then a linear gradient to 60% methanol at 5 minutes, followed by washing and re-equilibration steps. Steroids were identified by comparison to authentic reference standards, (THE, THF and 5 α THF purchased from Steraloids, Newport, RO, USA), with a matching retention time and identical mass transitions (MRMs) required for positive identification (Supporting Information Table S1 and Figure S1). Steroids were quantified relative to a calibration series ranging from 10-5000 ng/mL prepared in synthetic urine, including a blank. Steroid concentrations were calculated relative to an assigned internal standard. Validation of this method is described in the supplementary section (Supporting Information Table S2). Measurements of urinary cortisol and cortisone for supplementary analysis followed similar principles, and full details for this methodology are provided in the supplementary materials (Supporting Information Appendix S1, Table S1 and Figure S2).

2.4 | Statistical analysis

Data for continuous variables were not normally distributed. Mann-Whitney *U* test, Kruskal-Wallis test followed by Dunn's multiple comparisons test and Spearman's correlation test were used as appropriate. For multiple linear regression analysis, outcome variables were log-transformed to comply with the requisite statistical assumptions. For binary logistic regression analysis, urinary (THF+5 α THF)/THE ratio, eGFR and CRP did not comply with the linearity assumption of independent variables and log odds. These were therefore included as log-transformed variables (CRP) or as stratified variables (tertiles for urine (THF+5 α THF)/THE with limits ≤ 0.983 , 0.983-1.586 and > 1.586 ; clinical CKD stages for eGFR with ≤ 15 , 15-30, 30-45 and > 45 mL/min/1.73 m²). Cases with missing values were not included in multivariable analyses, but this applied to $\leq 3.2\%$ of cases for any reported model. Results were deemed statistically significant at $P < 0.05$. Sample size estimation considered that a covariate added to a baseline linear regression model for urine (THF+5 α THF)/THE with assumed $R^2 = 0.10$ producing an increment to $R^2 \geq 0.025$ will be identified as statistically significant at $P \leq 0.05$ with power 0.80 for $n = 282$. The final sample size included a redundancy margin of 15-20 per cent. Analyses were performed using IBM SPSS Statistics for Windows Version 23 (IBM Corp; Armonk, NY, USA).

3 | RESULTS

The clinical and laboratory characteristics of the study participants are summarized in Table 1 (for break-down by aetiology of renal disease see Supporting Information Table S3).

3.1 | Renal diagnosis and function

Previous studies have reported increasing GC activation by 11 β -HSD enzymes with declining renal function,^{4,6} which we tested in our larger cohort. Urine (THF+5 α THF)/THE was elevated in renal disease regardless of aetiology compared to healthy volunteers, except for polycystic renal disease (Figure 1A). Among cases with renal disease, urine (THF+5 α THF)/THE was lowest in polycystic renal disease and highest in diabetic nephropathy. As in previous reports, we found a negative but weak correlation of urine (THF+5 α THF)/THE with eGFR ($\rho = -0.116$, $P = 0.032$; Figure 1B). There was no association with urinary albumin-creatinine ratio (ACR; $\rho = 0.014$, $P = 0.796$; Figure 1C). These results consolidate previous observations that people with renal impairment have higher GC activation by 11 β -HSD.

3.2 | Inflammation

Chronic kidney disease is known to entail a pro-inflammatory state.⁹ This was apparent in our cohort in the negative correlation for eGFR with C-reactive protein (CRP; $\rho = -0.281$, $P < 0.001$; Figure 2A). Importantly, we identified a significant positive correlation between CRP and urine

TABLE 1 Cohort characteristics

Variable	Value
n	342
Age (y)	63 (50-75)
Female	134 (39%)
Ethnicity	
White	242 (71%)
South Asian	62 (18%)
Black	35 (10%)
Other	3 (1%)
Aetiology of renal disease	
Ischaemic/hypertensive	70 (20%)
Glomerulonephritis	70 (20%)
Polycystic	32 (9%)
Diabetic	31 (9%)
Obstructive/reflux	24 (7%)
Interstitial disease	19 (6%)
Not known and other	85 (25%)
No renal disease	11 (3%)
eGFR (mL/min/1.73 m ²)	28 (18-43)
Urine ACR (mg/mmol)	35.5 (5.4-120.6)
Diabetes	122 (36%)
HbA1c (mmol/mol)	42 (38-50)
C-reactive protein (mcg/mL)	2.7 (1.2-6.3)
Urine (THF+5 α THF)/THE	1.23 (0.86-1.80)

Continuous variables are reported as median (interquartile range) and categorical variables as frequency (percentage).

ACR, albumin-creatinine ratio; eGFR, estimated glomerular filtration rate; (THF+5 α THF)/THE, tetrahydrocortisol+5 α -tetrahydrocortisol/tetrahydrocortisone.

(THF+5 α THF)/THE ($\rho = 0.208$, $P < 0.001$; Figure 2B). This is reflected in the earlier observation of relatively low urine (THF+5 α THF)/THE in patients with polycystic kidney disease, as this subgroup also exhibited low CRP (Supporting Information Table S3). We constructed a multivariable linear regression model to explore independent determinants of urine (THF+5 α THF)/THE. Covariates included demographic factors, markers of renal function (eGFR, urine ACR), inflammation (CRP) and glycaemic control (HbA1c) (Table 2). Inflammation remained independently associated with urine (THF+5 α THF)/THE. However, there was no independent relationship between eGFR and urine (THF+5 α THF)/THE in the multiple linear regression model. This suggests that GC activation by 11 β -HSD is more closely associated with inflammation than with renal function in this CKD cohort.

3.3 | Diabetes mellitus

High 11 β -HSD1 activity leads to metabolic dysfunction and impaired insulin signalling, but this has not yet been tested in human CKD. Having identified that glucocorticoid activation by 11 β -HSD is elevated in CKD, we examined the association of urine (THF+5 α THF)/THE with

prevalent diabetes. Participants with known diabetes mellitus had higher urine (THF+5 α THF)/THE (median [interquartile range (IQR)]: 1.51 [0.97-1.87] vs 1.14 [0.81-1.61], $P = 0.007$; Figure 3A). eGFR was not significantly different between those with or without diabetes (median [IQR]: 26.0 [16.5-37.3] vs 29.1 [17.7-47.5], $P = 0.142$), but CRP was higher in those with diabetes (median [IQR]: 3.40 [2.12-9.51] vs 2.25 [1.08-4.84], $P < 0.001$). We controlled for the potential confounding influence of CRP, eGFR and demographic factors by using multivariable logistic regression analysis (Table 3; urine (THF+5 α THF)/THE and eGFR were categorized for this analysis to comply with the requisite statistical assumptions as detailed in the methods section). The association of high urine (THF+5 α THF)/THE with diabetes was independent of these covariates. The association also persisted after the inclusion of body mass index and family history of diabetes as additional covariates. This supports a link between glucocorticoid activation by 11 β -HSD and diabetes mellitus in our CKD cohort.

3.4 | HbA1c and poor glycaemic control

To further corroborate the link between elevated GC activation by 11 β -HSD with impaired glucose metabolism in CKD, we assessed the relationship of GC activation by 11 β -HSD with HbA1c. HbA1c was positively correlated with urine (THF+5 α THF)/THE ($\rho = 0.144$, $P = 0.008$; Figure 3B). HbA1c also exhibited a negative association with eGFR ($\rho = -0.127$, $P = 0.020$) and a positive association with CRP ($\rho = 0.337$, $P < 0.001$) in our cohort. We controlled for these covariates and demographic factors in a multiple linear regression analysis. Age, South Asian ethnicity and CRP remained associated with HbA1c ($P < 0.001$, $P < 0.001$ and $P = 0.001$, respectively; Supporting Information Table S5), but urine (THF+5 α THF)/THE did not show an independent association in the full cohort ($P = 0.659$; Supporting Information Table S5). We considered that the association of urine (THF+5 α THF)/THE with HbA1c could be weakened by inclusion of the non-diabetic population, as homeostatic mechanisms that counter-regulate increased insulin resistance are effective in this population and variability in HbA1c is low. Applying the same multiple linear regression model as before, we identified an independent association of urine (THF+5 α THF)/THE with HbA1c in the subgroup of patients with diabetes ($P = 0.034$; Supporting Information Table S5). Taken together, these results indicate an association of GC activation by 11 β -HSD and disturbances in glucose metabolism in the context of renal impairment.

3.5 | Urinary cortisol-cortisone ratio

A supplementary analysis of urinary cortisol-cortisone ratio identified no significant association with eGFR, CRP, prevalent diabetes mellitus or HbA1c (Supporting Information Figure S3).

4 | DISCUSSION

Previous studies in patients with CKD have suggested that increasing (THF+5 α THF)/THE ratios, favouring systemic cortisol




FIGURE 1 Association of urine (THF+5 α THF)/THE with renal diagnosis and function. A, Urine (THF+5 α THF)/THE is higher in renal disease regardless of aetiology, except for polycystic renal disease. Urine (THF+5 α THF)/THE is significantly different for polycystic vs diabetic renal disease, but not for other comparisons by aetiology of renal disease. (THF+5 α THF)/THE is displayed on a discontinuous scale to show outliers that were included in the analysis. Beams and whiskers indicate group medians and interquartile ranges, respectively; numbers in parentheses indicate cases per group. Group comparisons used Dunn's multiple comparisons test: *P < 0.05, **P < 0.01, ***P < 0.001 vs no renal disease. B, Urine (THF+5 α THF)/THE correlates negatively with renal function, but (C) does not correlate with albuminuria. Urinary ACR is displayed on a log scale. Spearman's test was used to assess correlations. ACR, albumin-creatinine ratio; eGFR, estimated glomerular filtration rate; (THF+5 α THF)/THE, tetrahydrocortisol+5 α -tetrahydrocortisol/tetrahydrocortisone

activation, are determined by declining renal function and attenuated renal steroid clearance by 11 β -HSD2.^{4,5} Our study confirmed that GC activation by 11 β -HSD is elevated in CKD, but identified inflammation as a crucial modifying factor in this setting. Furthermore, we identified an association between increasing (THF+5 α THF)/THE ratio with impaired glucose control in this CKD cohort.

Inflammation, measured as CRP, was the dominant explanatory variable for urine (THF+5 α THF)/THE in our data and significantly diminished the effect of eGFR as a covariate. The association between urine (THF+5 α THF)/THE and eGFR was not as strong as values previously reported in the literature.^{4,6} Cohorts in previous studies were smaller, used sampling methodologies with greater potential for bias and included a majority of participants with eGFR >60 mL/min/1.73 m². In contrast, the cohort in this study is more representative of a high-risk CKD population.

Previous studies did not control for inflammation, which is concomitant with renal impairment. Inflammation is a potent inducer of 11 β -HSD1 expression and activity, with significant increases in cortisol activation by 11 β -HSD1 seen in several inflammatory diseases.^{11,12,14,34,36,37} Whilst this study cannot accurately discriminate between the 11 β -HSD types 1 and 2

contributions to systemic GC metabolism, it is unlikely that our findings are solely attributable to loss of renal cortisol inactivation by 11 β -HSD2. The inflammatory cytokines TNF α and IL-1 β , which accumulate in uraemia, are potent inducers of 11 β -HSD1.^{9,11} Furthermore, studies in human hepatocytes and animal models of uraemia report marked increases in 11 β -HSD1 activity.^{7,8} Our results are therefore consistent with a growing body of evidence that increased inflammatory induction of 11 β -HSD1 contributes considerably to abnormal GC metabolism in patients with CKD.

In this study, we demonstrate that diabetes, and HbA1c among patients with diabetes, is associated with elevated urine (THF+5 α THF)/THE in CKD. The association of impaired glycaemic control with shifts in cortisol metabolism remained after adjustment for age, sex, ethnicity, renal function and inflammation. These results align with a large body of evidence that has established insulin resistance as a consequence of increased 11 β -HSD1 activity in animal models and human disease.^{7,23,24,26-29} The absence of a correlation between urine (THF+5 α THF)/THE and HbA1c in the non-diabetic subgroup can be explained by a lack of change in HbA1c regardless of insulin resistance, as accompanying insulin secretion increases sufficiently to maintain glycaemic




FIGURE 2 Correlation of inflammation with renal function and urine (THF+5 α THF)/THE. A, Inflammation, measured by C-reactive protein, is negatively correlated with eGFR and (B) positively correlated with urine (THF+5 α THF)/THE ratio. C-reactive protein is displayed on a log scale. Spearman's test was used to assess correlations. eGFR, estimated glomerular filtration rate; (THF+5 α THF)/THE, tetrahydrocortisol+5 α -tetrahydrocortisol/tetrahydrocortisone

TABLE 2 Independent determinants of 11 β -HSD-mediated glucocorticoid activation (n = 337)

Variable	B	SE	β	t	P
Age (y)	1.13×10^{-3}	1.94×10^{-3}	0.035	0.58	0.560
Sex					
Male	Reference				
Female	-0.143	0.058	-0.130	-2.47	0.014
Ethnicity					
White	Reference				
South Asian	0.104	0.078	0.074	1.33	0.185
Black	0.208	0.094	0.119	2.20	0.028
Other	-0.565	0.300	-0.099	-1.89	0.060
eGFR (mL/min/1.73 m ²)	-1.76×10^{-3}	1.34×10^{-3}	-0.075	-1.31	0.191
Urine ACR (mg/mmol)	3.43×10^{-5}	2.40×10^{-4}	0.008	0.14	0.886
C-reactive protein (mcg/ml)	6.72×10^{-3}	2.14×10^{-3}	0.172	3.14	0.002
HbA1c (mmol/mol)	3.08×10^{-3}	2.39×10^{-3}	0.074	1.29	0.198

Multivariable linear regression analysis with dependent variable \log_e -transformed urine (THF+5 α THF)/THE. Adjusted $R^2 = 0.083$. Exclusion of the 11 healthy volunteer cases from the analysis or substitution of HbA1c with diagnosis of diabetes does not significantly impact on the displayed parameters.

ACR, albumin-creatinine ratio; eGFR, estimated glomerular filtration rate; (THF+5 α THF)/THE, tetrahydrocortisol+5 α -tetrahydrocortisol/tetrahydrocortisone; 11 β -HSD, 11 β -hydroxysteroid dehydrogenase.

control.¹⁸ Our data therefore remain consistent with a role for 11 β -HSD1 in insulin resistance in human CKD.

Inflammation is a known driver for insulin resistance in CKD. This is evident by CRP showing a negative correlation with eGFR and an independent positive correlation with HbA1c in this study. Pro-inflammatory cytokines TNF α and IL-1 accumulate in CKD in serum, as well as in insulin target tissues, where they act on IRS-1 and PKB/Akt to impede post-receptor insulin signal transduction.^{15,16} In the same tissues, *in vitro* experiments have demonstrated the capability of TNF α and IL-1 β to upregulate 11 β -HSD1, which in turn also causes insulin resistance through action on IRS-1 and PKB/Akt.^{11,25} Existing biochemical data therefore illustrate a coherent pathway through which inflammation-mediated

upregulation of 11 β -HSD1 leads to insulin resistance. Importantly, this opens 11 β -HSD1 inhibition as a therapeutic target in CKD to treat insulin resistance—and possibly other disturbances like dyslipidaemia—for which a proof of concept experiment in rodents has already been successful.⁷

Urinary cortisol-cortisone ratio exhibited a moderate correlation with renal 11 β -HSD2 expression in a previous study by Quinkler et al.⁶ An association between renal function and cortisol-cortisone ratios in 24 hour urine samples has been described in some but not all studies.^{4,6,40} In this study, we did not identify any significant correlations between urinary cortisol-cortisone ratios with eGFR, nor with CRP or Hb1Ac. These divergent results may reflect significant heterogeneity between study populations,




FIGURE 3 Association of urine (THF+5 α THF)/THE with diabetes mellitus and glycaemic control. A, Urinary (THF+5 α THF)/THE ratio was elevated in prevalent diabetes and (B) correlated positively with HbA1c, a measure of poor glycaemic control. (THF+5 α THF)/THE is displayed on a discontinuous scale to show outliers that were included in the analysis. Beams and whiskers indicate group medians and interquartile ranges, respectively; numbers in parentheses indicate cases per group. The Mann-Whitney *U* test was used to compare groups; Spearman's test was used to assess correlations. (THF+5 α THF)/THE, tetrahydrocortisol+5 α -tetrahydrocortisol/tetrahydrocortisone

TABLE 3 Adjusted odds ratio for the association of glucocorticoid activation by 11 β -HSD with prevalent diabetes mellitus

	n	Urine (THF+5 α THF)/THE						
		Low tertile	Middle tertile			High tertile		
			OR	95% CI	P	OR	95% CI	P
Unadjusted	342	Ref.	1.36	0.77-2.42	0.289	2.57	1.47-4.47	0.001
Model A	342	Ref.	1.30	0.70-2.40	0.403	1.97	1.07-3.62	0.029
Model B	331	Ref.	1.22	0.63-2.35	0.556	2.09	1.09-4.02	0.027

Binary logistic regression analysis for the association of urine (THF+5 α THF)/THE (stratified by tertiles) with prevalent diabetes. Model A: adjustment for age, sex, ethnicity, estimated glomerular filtration rate (stratified for ≤ 15 , 15-30, 30-45 and >45 mL/min/1.73 m²) and C-reactive protein (log_e-transformed). Model B: as in Model A plus adjustment for family history of diabetes and body mass index. The parameters for all covariates are reported in Table S4.

(THF+5 α THF)/THE, tetrahydrocortisol+5 α -tetrahydrocortisol/tetrahydrocortisone; 11 β -HSD, 11 β -hydroxysteroid dehydrogenase.

or that spot urines lack sufficient sensitivity to detect these changes.

Several strengths and limitations are worth noting about this study. The observational design produced results that demonstrate associations between shifts in glucocorticoid metabolism, inflammation and impaired glucose metabolism, but cannot confirm causal relationships. By choosing this design, it was nevertheless possible to test predictions from pre-clinical models, which link inflammation with raised 11 β -HSD1 activity and insulin resistance, in the clinical setting and thereby providing new evidence for the significance of this pathway in human disease. The study cohort was large and diverse, which permitted control for potential confounders, strengthens the validity of the results and enhances their relevance for people with CKD. Measuring urine metabolite ratios by liquid chromatography-mass spectrometry as indicator of 11 β -HSD activity, whilst offering high convenience for a large study population, limits conclusions about 11 β -HSD type- or tissue-specific alterations. Alterations in 11 β -HSD activity lead to much more pronounced shifts of cortisol-cortisone equilibrium in local tissues than in circulation,⁷ meaning that correlations of inflammation and insulin resistance with local 11 β -HSD activities could be much stronger than what can be observed by measuring systemic metabolite ratios. Future research with methodologies that characterize 11 β -HSD type- and tissue-specific alterations

in humans with CKD will be valuable for building on our results. Finally, it would be relevant to investigate whether elevated GC activation by 11 β -HSD associates not only with impaired glycaemic control, but also with cardiovascular morbidity, progression of renal disease or mortality.

Examination of basal serum cortisol levels or total urinary GC excretion would add additional validation of our findings, helping delineate potential contributions of the hypothalamic-pituitary-adrenal (HPA) axis to our results. Without timed serum samples or urine samples from a fixed collection period for our cohort, we were unable to control directly for systemic cortisol levels or HPA axis activity. Nevertheless, previous studies validated the specificity of urine (THF+5 α THF)/THE for alterations in 11 β -HSD activity over changes in HPA axis activity and found no correlation between total GC metabolite excretion as a measure of HPA axis activity and renal function.^{4,6,31,32} Neither do fluctuations in systemic cortisol interfere with urine (THF+5 α THF)/THE.⁴¹ Importantly, basal cortisol levels, as well as the fraction of protein bound cortisol (90%-95%), do not change significantly with renal impairment.^{42,43} We therefore argue that associations with urine (THF+5 α THF)/THE in our study reflect systemic 11 β -HSD regulation rather than systemic cortisol levels or HPA axis activity.

In conclusion, this study assessed systemic cortisol metabolism by 11 β -HSD enzymes in a large cohort of patients with pre-dialysis chronic

renal impairment. We identified inflammation as a major determinant of GC activation by 11 β -HSD and as a confounder in the correlation of GC activation with renal impairment, thereby expanding on knowledge from previous studies. Higher GC activation by 11 β -HSD was associated with disturbances in glucose homeostasis, offering novel evidence for its clinical significance in patients with CKD. Our data agree with studies from preclinical and non-renal settings that inflammation-induced upregulation of 11 β -HSD1 can contribute to metabolic pathology. This study therefore adds credibility to the potential of 11 β -HSD1 inhibitors to reduce insulin resistance in populations with pro-inflammatory conditions and improve their cardiovascular risk.

ACKNOWLEDGEMENTS

This study was supported by the Arthritis Research UK grants (Reference: 20843). The RIISC study is supported by JABBS Foundation (Birmingham, United Kingdom) and The Queen Elizabeth Hospital Birmingham Charity. MS is supported by an Academic Clinical Fellowship from the National Institute for Health Research UK. NAW is supported by a Joint Basic and Clinical PhD Studentship from the Wellcome Trust (reference 105479/Z/14/Z). The authors would like to acknowledge the support of the staff in the renal outpatient department, the NIHR/Wellcome Trust Clinical Research Facility and the research and development department at University Hospital Birmingham, together with all the individuals who participated in the study. We would like to thank Mary Dutton and the renal research nursing staff at Queen Elizabeth Hospital Birmingham for facilitating access to resources from the RIISC study.

DISCLOSURE

All authors declare that they have no relevant financial interests.

AUTHORS' CONTRIBUTIONS

MSS, PGN, PC, RSH and LH contributed to research idea and study design. MSS, AET, AF, NAW and RSH involved in data acquisition. MSS, AET, AF, DC, PGN, CJF, WA, PC, RSH and LH performed data analysis/interpretation. MSS and PGN performed statistical analysis. AET, DC, PGN, CJF, WA, PC, RSH and LH involved in supervision or mentorship. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

ORCID

Rowan S. Hardy  <http://orcid.org/0000-0001-6938-6739>

REFERENCES

- Sharma ST, Nieman LK, Feelders RA. Comorbidities in Cushing's disease. *Pituitary*. 2015;18(2):188-194.
- Chapman K, Holmes M, Seckl J. 11 beta-Hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. *Physiol Rev*. 2013;93(3):1139-1206.
- Stewart PM, Krozowski ZS. 11 beta-Hydroxysteroid dehydrogenase. *Vitam Horm*. 1999;57:249-324.
- Henschkowski J, Stuck AE, Frey BM, et al. Age-dependent decrease in 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) activity in hypertensive patients. *Am J Hypertens*. 2008;21(6):644-649.
- Mongia A, Vecker R, George M, et al. Role of 11betaHSD type 2 enzyme activity in essential hypertension and children with chronic kidney disease (CKD). *J Clin Endocrinol Metab*. 2012;97(10):3622-3629.
- Quinkler M, Zehnder D, Lepenies J, et al. Expression of renal 11beta-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function. *Eur J Endocrinol*. 2005;153(2):291-299.
- Chapagain A, Caton PW, Kieswich J, et al. Elevated hepatic 11beta-hydroxysteroid dehydrogenase type 1 induces insulin resistance in uremia. *Proc Natl Acad Sci USA*. 2014;111(10):3817-3822.
- Li M, Ellis E, Johansson H, et al. Changes in gluconeogenesis and intracellular lipid accumulation characterize uremic human hepatocytes ex vivo. *Am J Physiol Gastrointest Liver Physiol*. 2016;310(11):G952-G961.
- Gupta J, Mitra N, Kanetsky PA, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. *Clin J Am Soc Nephrol*. 2012;7(12):1938-1946.
- Hardy RS, Filer A, Cooper MS, et al. Differential expression, function and response to inflammatory stimuli of 11beta-hydroxysteroid dehydrogenase type 1 in human fibroblasts: a mechanism for tissue-specific regulation of inflammation. *Arthritis Res Ther*. 2006;8(4):R108.
- Ahasan MM, Hardy R, Jones C, et al. Inflammatory regulation of glucocorticoid metabolism in mesenchymal stromal cells. *Arthritis Rheum*. 2012;64(7):2404-2413.
- Hardy R, Rabbitt EH, Filer A, et al. Local and systemic glucocorticoid metabolism in inflammatory arthritis. *Ann Rheum Dis*. 2008;67(9):1204-1210.
- Hardy RS, Doig CL, Hussain Z, et al. 11beta-Hydroxysteroid dehydrogenase type 1 within muscle protects against the adverse effects of local inflammation. *J Pathol*. 2016;240(4):472-483.
- Stegk JP, Ebert B, Martin HJ, Maser E. Expression profiles of human 11beta-hydroxysteroid dehydrogenases type 1 and type 2 in inflammatory bowel diseases. *Mol Cell Endocrinol*. 2009;301(1-2):104-108.
- Liao M-T, Sung C-C, Hung K-C, Wu C-C, Lo L, Lu K-C. Insulin resistance in patients with chronic kidney disease. *J Biomed Biotechnol*. 2012;2012:691369.
- Spoto B, Pisano A, Zoccali C. Insulin resistance in chronic kidney disease: a systematic review. *Am J Physiol Renal Physiol*. 2016;311(6):F1087-F1108.
- Zanetti M, Barazzoni R, Guarnieri G. Inflammation and insulin resistance in uremia. *J Ren Nutr*. 2008;18(1):70-75.
- Pham H, Robinson-Cohen C, Biggs ML, et al. Chronic kidney disease, insulin resistance, and incident diabetes in older adults. *Clin J Am Soc Nephrol*. 2012;7(4):588-594.
- Fliser D, Pacini G, Engelleiter R, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. *Kidney Int*. 1998;53(5):1343-1347.
- Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. *J Am Soc Nephrol*. 2013;24(2):302-308.
- Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. *Lancet Diabetes Endocrinol*. 2017;5(6):431-437.
- Menon V, Greene T, Pereira AA, et al. Glycosylated hemoglobin and mortality in patients with nondiabetic chronic kidney disease. *J Am Soc Nephrol*. 2005;16(11):3411-3417.

23. Lindsay RS, Wake DJ, Nair S, et al. Subcutaneous adipose 11beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. *J Clin Endocrinol Metab.* 2003;88(6):2738-2744.
24. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. *Science.* 2001;294(5549):2166-2170.
25. Morgan SA, Sherlock M, Gathercole LL, et al. 11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. *Diabetes.* 2009;58(11):2506-2515.
26. Kotelevtsev Y, Holmes MC, Burchell A, et al. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. *Proc Natl Acad Sci USA.* 1997;94(26):14924-14929.
27. Morgan SA, McCabe EL, Gathercole LL, et al. 11beta-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. *Proc Natl Acad Sci USA.* 2014;111(24):E2482-E2491.
28. Feig PU, Shah S, Hermanowski-Vosatka A, et al. Effects of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. *Diabetes Obes Metab.* 2011;13(6):498-504.
29. Rosenstock J, Banarer S, Fonseca VA, et al. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. *Diabetes Care.* 2010;33(7):1516-1522.
30. Andrew R, Smith K, Jones GC, Walker BR. Distinguishing the activities of 11beta-hydroxysteroid dehydrogenases in vivo using isotopically labeled cortisol. *J Clin Endocrinol Metab.* 2002;87(1):277-285.
31. Courtney R, Stewart PM, Toh M, Ndongo MN, Calle RA, Hirshberg B. Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor. *J Clin Endocrinol Metab.* 2008;93(2):550-556.
32. Lawson AJ, Walker EA, Lavery GG, et al. Cortisone-reductase deficiency associated with heterozygous mutations in 11beta-hydroxysteroid dehydrogenase type 1. *Proc Natl Acad Sci USA.* 2011;108(10):4111-4116.
33. Stringer S, Sharma P, Dutton M, et al. The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol. *BMC Nephrol.* 2013;14:95.
34. Nanus DE, Filer AD, Yeo L, et al. Differential glucocorticoid metabolism in patients with persistent versus resolving inflammatory arthritis. *Arthritis Res Ther.* 2015;17:121.
35. Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. *J Clin Endocrinol Metab.* 2011;96(12):3775-3784.
36. Cooper MS, Kriel H, Sayers A, et al. Can 11beta-hydroxysteroid dehydrogenase activity predict the sensitivity of bone to therapeutic glucocorticoids in inflammatory bowel disease? *Calcif Tissue Int.* 2011;89(3):246-251.
37. Nanus DE, Filer AD, Hughes B, et al. TNFalpha regulates cortisol metabolism in vivo in patients with inflammatory arthritis. *Ann Rheum Dis.* 2015;74(2):464-469.
38. Gambineri A, Fanelli F, Tomassoni F, et al. Tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls. *Eur J Endocrinol.* 2014;171(1):47-57.
39. Lutz SZ, Peter A, Machicao F, et al. Genetic variation in the 11beta-hydroxysteroid-dehydrogenase 1 gene determines NAFLD and visceral obesity. *J Clin Endocrinol Metab.* 2016;101(12):4743-4751.
40. Hammer F, Edwards NC, Hughes BA, et al. The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. *Clin Endocrinol.* 2010;73(5):566-572.
41. Jerjes WK, Peters TJ, Taylor NF, Wood PJ, Wessely S, Cleare AJ. Diurnal excretion of urinary cortisol, cortisone, and cortisol metabolites in chronic fatigue syndrome. *J Psychosom Res.* 2006;60(2):145-153.
42. Homma M, Tanaka A, Hino K, et al. Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure. *Metabolism.* 2001;50(7):801-804.
43. Oguz Y, Oktenli C, Ozata M, et al. The midnight-to-morning urinary cortisol increment method is not reliable for the assessment of hypothalamic-pituitary-adrenal insufficiency in patients with end-stage kidney disease. *J Endocrinol Invest.* 2003;26(7):609-615.
44. Kawai S, Ichikawa Y, Homma M. Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure. *J Clin Endocrinol Metab.* 1985;60(5):848-854.
45. Rosman PM, Benn R, Kay M, Tito J, Wallace EZ. Cortisol binding in uremic plasma. I. Absence of abnormal cortisol binding to cortisol binding to corticosteroid-binding globulin. *Nephron.* 1984;37(3):160-165.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Sagmeister MS, Taylor AE, Fenton A, et al. Glucocorticoid activation by 11 β -hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: A cross-sectional study. *Clin Endocrinol.* 2018;00:1-9. <https://doi.org/10.1111/cen.13889>